DUBLIN, July 20, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/cb93zs/cardiometabolic) has announced the addition of the "Cardiometabolic Drug News Issue" newsletter to their offering.
Afrezza's discounted pricing is in line with our existing view that such a strategy is critical to the product's commercial appeal. However, contraindications, side effects, and competition will continue to prevent Afrezza from gaining a sizeable share of the fast-acting insulin market.
Cardiometabolic Drug News covers major developments in the areas of Type II Diabetes, Obesity and Cardiovascular Disease. The monthly newsletter will provide you with the latest news and developments of global companies involved in these therapeutic areas. Being comprehensive and easy to read, Cardiometabolic Drug News is the time-efficient way to keep up with every pharma development you need to know.
Regular sections include:
- Corporate Activity - The latest noteworthy cardiometabolic-related acquisitions, mergers, divestitures and restructurings
- Agreements - New deals, alliances and collaborations
- Product News - The latest product filings, approvals, launches, withdrawals and litigations and patent-related developments worldwide
- R&D - News of pipeline updates, late-stage clinical trials, and patent-related developments
Your Benefits:
- Track the companies that are shaping the industry - identify potential partnering opportunities, keep track of your competitors and highlight acquisition targets
- Understand the latest developments in current and upcoming treatments and research - be at the forefront of research and development
- Monitor the highlights from major conferences and meetings across the world - never miss another update
- Keep ahead of every important development
Key Topics Covered:
1. Afrezza Aggressive Pricing Strategy View Playing Out
2. Agreements
3. BMS/uniQure Collaborate On Cardiovascular Gene Therapy
- Taxus Cardium/Dr Reddy's Sign Deal For Generx
4. Merck/Astellas Sign Japanese Co-Commercialisation Deal For Januvia/Suglat Combination Product - Corporate Activity
- AOP Orphan/Rigi Healthcare Create Rigi Orphan USA To Focus On Rare Diseases
- Cardio3 BioSciences Changes Name To Celyad
- Omeicos Raises Funds To Advance Lead Candidate In Atrial Fibrillation
5. Takeda Agrees To Settle Actos Product Liability Lawsuits In US
- InCarda Raises Funds To Advance Inhaled Cardiotherapeutic Programme
- Novo Nordisk Opens Insulin Manufacturing Facility In Russia - Product News
- BI Seeks FDA Approval For Additional Pradaxa Indication
6. Daiichi Sankyo's Once-Daily Lixiana Receives Positive CHMP Opinion
- FDA Approves Corlanor For Chronic HF
- FDA Advisory Committee Recommends Approval Of TMC's Cangrelor
7. BI's Idarucizumab Gains FDA Priority Review As Reversal Agent For Pradaxa
- Saxenda Available In US
- FDA Approves Expanded Dosing Time For Aggrastat
- RegeneRx Secures US Patent Allowance Covering TB4
8. FDA Advisory Committee Recommends Takeda's Alogliptin For Type II Diabetes
- FDA Grants Priority Review To Brilinta For Patients With History Of MI
9. FDA Panel To Review Data Supporting Repatha BLA In High Cholesterol Treatment
- FDA Panel Recommends New Saxagliptin CV Safety Information In Type II Diabetes
- AOP Orphan Launches Lojuxta In Australia For HoFH
10. Patent Challenge Exposes Qsymia's Weaknesses
11. Actavis Initiates Ambrisentan Patent Challenge
- Lixiana Approved In Switzerland For NVAF/VTE
12. Two Additional US Patents Issued For Vivus' Qsymia
- EC Approves Kengrexal/Orbactiv/Raplixa
13. Biocon Gains Mexico Insulin Glargine Approval
- FDA Accepts Tresiba/Ryzodeg Resubmissions For Review
- Aurobindo Gains US Sildenafil Approval
- Teva Launches Argatroban Injection In US R&D
- Celladon Reports Negative Results For CUPID2 Trial Of Mydicar In Advanced HF
14. Portola's Andexanet Alfa Achieves Primary Endpoint For Prolonged Reversal Of Eliquis
- Chinese Stem Cell Patent Covering Stempeucel Granted
- Resverlogix Granted Chinese Patents Covering RVX-208
15. FDA Grants Fast Track Designation To Gencaro
- Reata Receives FDA ODD For Bardoxolone Methyl In PAH
- CymaBay Initiates Phase II Study Of MBX-8025 In HoFH
- Heart Metabolics/FDA Enter SPA Agreement For Perhexiline Phase III HCM Trial
16. Eisai/Arena Complete Registrational Trials Of Lorcaserin ER Formulation
For more information visit http://www.researchandmarkets.com/research/cb93zs/cardiometabolic
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
